Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies
Objective: The objectives of the present study were to demonstrate the influence of neutrophils, platelets, and neutrophil-lymphocyte ratio (NLR) in the ovarian cancer prognosis and to compare these parameters with benign ovarian neoplasms. Materials and Methods: Records of patients underwent surger...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and therapeutics 2019-10, Vol.15 (6), p.1226-1230 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1230 |
|---|---|
| container_issue | 6 |
| container_start_page | 1226 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 15 |
| creator | Nomelini, Rosekeila Carrijo Chiovato, Ana Abdulmassih, Fernanda da Silva, Rafael de Tavares-Murta, Beatriz Murta, Eddie |
| description | Objective: The objectives of the present study were to demonstrate the influence of neutrophils, platelets, and neutrophil-lymphocyte ratio (NLR) in the ovarian cancer prognosis and to compare these parameters with benign ovarian neoplasms.
Materials and Methods: Records of patients underwent surgery for ovarian cysts were evaluated. There were 72 malignant neoplasms and 213 benign neoplasms. Age, parity, histologic type, tumor stage, type of surgery performed, chemotherapy, disease-free survival, serum levels of tumor markers, neutrophils, lymphocytes, platelets, and NRL were recorded. The Mann-Whitney, the Chi-square test and multiple linear regression were used. A P-value < 0.05 was established as the significance level.
Results: Higher values of platelets, neutrophils, and NLR were found in malignant tumors (P = 0.0132, P = 0.0208, and P < 0.0001, respectively), while lymphocytes values were higher in benign group (P < 0.0001). Preoperative platelet count 300,000/mm3 was related to less aggressive histological types (P = 0.0148). NLR 24 months had most often neutropenia during chemotherapy (P = 0.0482). After multivariate analysis, platelets, NLR, and serum levels of CA15.3 were considered independent variables related to tumor staging (P = 0.028, P = 0.028, and P = 0.035, respectively).
Conclusion: NLR and serum levels of platelets may represent potential prognostic factors in ovarian cancer, and they may also serve as therapeutic targets in the future treatment strategies. |
| doi_str_mv | 10.4103/jcrt.JCRT_304_17 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2333600739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2333600739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429h-d806f67954ed43ef5f55b425444ed2713e454cc9876745bad7f20af0992996d93</originalsourceid><addsrcrecordid>eNp1kd1LHDEUxUOp1FX73icJ9KUvs-ZzMnmUpfUDURB9DtlMxs2aScYk02X_-86yKlLw6cLld849nAvAD4zmDCN6tjapzK8X9w-KIqaw-AJmWMqmYpg2X8EMSUErzBpyCI5yXiPEBSHNN3BIcSObmpMZULd2LCkOK-erEiu_7YdVNNtiYdLFRahDCwevi_W2QBPHUKDOcEjxKcRcnIGdNiWmDF2A8a9OTgfYa--egg7G2XwCDjrts_3-Oo_B45_fD4vL6ubu4mpxflMZRuSqahtUd7WQnNmWUdvxjvMlI5yxaUEEppZxZoxsRC0YX-pWdATpDklJpKxbSY_Br73vFO1ltLmo3mVjvdfBxjErQimtERJ0h_78D13HMYUp3Y5Cgk1HyEShPWVSzDnZTg3J9TptFUZqV77ala8-lD9JTl-Nx2Vv23fBW9sTsNgDm-iLTfnZjxub1MQ-h7j51FhhQur3R9F_xKSZTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2330748762</pqid></control><display><type>article</type><title>Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies</title><source>MEDLINE</source><source>Medknow Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nomelini, Rosekeila ; Carrijo Chiovato, Ana ; Abdulmassih, Fernanda ; da Silva, Rafael de ; Tavares-Murta, Beatriz ; Murta, Eddie</creator><creatorcontrib>Nomelini, Rosekeila ; Carrijo Chiovato, Ana ; Abdulmassih, Fernanda ; da Silva, Rafael de ; Tavares-Murta, Beatriz ; Murta, Eddie</creatorcontrib><description>Objective: The objectives of the present study were to demonstrate the influence of neutrophils, platelets, and neutrophil-lymphocyte ratio (NLR) in the ovarian cancer prognosis and to compare these parameters with benign ovarian neoplasms.
Materials and Methods: Records of patients underwent surgery for ovarian cysts were evaluated. There were 72 malignant neoplasms and 213 benign neoplasms. Age, parity, histologic type, tumor stage, type of surgery performed, chemotherapy, disease-free survival, serum levels of tumor markers, neutrophils, lymphocytes, platelets, and NRL were recorded. The Mann-Whitney, the Chi-square test and multiple linear regression were used. A P-value < 0.05 was established as the significance level.
Results: Higher values of platelets, neutrophils, and NLR were found in malignant tumors (P = 0.0132, P = 0.0208, and P < 0.0001, respectively), while lymphocytes values were higher in benign group (P < 0.0001). Preoperative platelet count 300,000/mm3 was related to less aggressive histological types (P = 0.0148). NLR <3 was related to the initial stages (P = 0.0053), and patients with disease-free survival >24 months had most often neutropenia during chemotherapy (P = 0.0482). After multivariate analysis, platelets, NLR, and serum levels of CA15.3 were considered independent variables related to tumor staging (P = 0.028, P = 0.028, and P = 0.035, respectively).
Conclusion: NLR and serum levels of platelets may represent potential prognostic factors in ovarian cancer, and they may also serve as therapeutic targets in the future treatment strategies.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.JCRT_304_17</identifier><identifier>PMID: 31898652</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Biomarkers ; Blood platelets ; Blood tests ; Cancer therapies ; Chemotherapy ; Clinical Decision-Making ; Cysts ; Disease ; Disease Management ; Female ; Humans ; Leukocyte Count ; Lymphocyte Count ; Lymphocytes ; Medical prognosis ; Metastasis ; Neoplasm Grading ; Neoplasm Staging ; Neutropenia ; Neutrophils ; Ovarian cancer ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - therapy ; Patients ; Platelet Count ; Prognosis ; Regression analysis ; Software ; Surgery ; Tumors</subject><ispartof>Journal of cancer research and therapeutics, 2019-10, Vol.15 (6), p.1226-1230</ispartof><rights>2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429h-d806f67954ed43ef5f55b425444ed2713e454cc9876745bad7f20af0992996d93</citedby><cites>FETCH-LOGICAL-c429h-d806f67954ed43ef5f55b425444ed2713e454cc9876745bad7f20af0992996d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27458,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31898652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nomelini, Rosekeila</creatorcontrib><creatorcontrib>Carrijo Chiovato, Ana</creatorcontrib><creatorcontrib>Abdulmassih, Fernanda</creatorcontrib><creatorcontrib>da Silva, Rafael de</creatorcontrib><creatorcontrib>Tavares-Murta, Beatriz</creatorcontrib><creatorcontrib>Murta, Eddie</creatorcontrib><title>Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Objective: The objectives of the present study were to demonstrate the influence of neutrophils, platelets, and neutrophil-lymphocyte ratio (NLR) in the ovarian cancer prognosis and to compare these parameters with benign ovarian neoplasms.
Materials and Methods: Records of patients underwent surgery for ovarian cysts were evaluated. There were 72 malignant neoplasms and 213 benign neoplasms. Age, parity, histologic type, tumor stage, type of surgery performed, chemotherapy, disease-free survival, serum levels of tumor markers, neutrophils, lymphocytes, platelets, and NRL were recorded. The Mann-Whitney, the Chi-square test and multiple linear regression were used. A P-value < 0.05 was established as the significance level.
Results: Higher values of platelets, neutrophils, and NLR were found in malignant tumors (P = 0.0132, P = 0.0208, and P < 0.0001, respectively), while lymphocytes values were higher in benign group (P < 0.0001). Preoperative platelet count 300,000/mm3 was related to less aggressive histological types (P = 0.0148). NLR <3 was related to the initial stages (P = 0.0053), and patients with disease-free survival >24 months had most often neutropenia during chemotherapy (P = 0.0482). After multivariate analysis, platelets, NLR, and serum levels of CA15.3 were considered independent variables related to tumor staging (P = 0.028, P = 0.028, and P = 0.035, respectively).
Conclusion: NLR and serum levels of platelets may represent potential prognostic factors in ovarian cancer, and they may also serve as therapeutic targets in the future treatment strategies.</description><subject>Biomarkers</subject><subject>Blood platelets</subject><subject>Blood tests</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical Decision-Making</subject><subject>Cysts</subject><subject>Disease</subject><subject>Disease Management</subject><subject>Female</subject><subject>Humans</subject><subject>Leukocyte Count</subject><subject>Lymphocyte Count</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Neutropenia</subject><subject>Neutrophils</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Patients</subject><subject>Platelet Count</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Software</subject><subject>Surgery</subject><subject>Tumors</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kd1LHDEUxUOp1FX73icJ9KUvs-ZzMnmUpfUDURB9DtlMxs2aScYk02X_-86yKlLw6cLld849nAvAD4zmDCN6tjapzK8X9w-KIqaw-AJmWMqmYpg2X8EMSUErzBpyCI5yXiPEBSHNN3BIcSObmpMZULd2LCkOK-erEiu_7YdVNNtiYdLFRahDCwevi_W2QBPHUKDOcEjxKcRcnIGdNiWmDF2A8a9OTgfYa--egg7G2XwCDjrts_3-Oo_B45_fD4vL6ubu4mpxflMZRuSqahtUd7WQnNmWUdvxjvMlI5yxaUEEppZxZoxsRC0YX-pWdATpDklJpKxbSY_Br73vFO1ltLmo3mVjvdfBxjErQimtERJ0h_78D13HMYUp3Y5Cgk1HyEShPWVSzDnZTg3J9TptFUZqV77ala8-lD9JTl-Nx2Vv23fBW9sTsNgDm-iLTfnZjxub1MQ-h7j51FhhQur3R9F_xKSZTw</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Nomelini, Rosekeila</creator><creator>Carrijo Chiovato, Ana</creator><creator>Abdulmassih, Fernanda</creator><creator>da Silva, Rafael de</creator><creator>Tavares-Murta, Beatriz</creator><creator>Murta, Eddie</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20191001</creationdate><title>Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies</title><author>Nomelini, Rosekeila ; Carrijo Chiovato, Ana ; Abdulmassih, Fernanda ; da Silva, Rafael de ; Tavares-Murta, Beatriz ; Murta, Eddie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429h-d806f67954ed43ef5f55b425444ed2713e454cc9876745bad7f20af0992996d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers</topic><topic>Blood platelets</topic><topic>Blood tests</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical Decision-Making</topic><topic>Cysts</topic><topic>Disease</topic><topic>Disease Management</topic><topic>Female</topic><topic>Humans</topic><topic>Leukocyte Count</topic><topic>Lymphocyte Count</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Neutropenia</topic><topic>Neutrophils</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Patients</topic><topic>Platelet Count</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Software</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nomelini, Rosekeila</creatorcontrib><creatorcontrib>Carrijo Chiovato, Ana</creatorcontrib><creatorcontrib>Abdulmassih, Fernanda</creatorcontrib><creatorcontrib>da Silva, Rafael de</creatorcontrib><creatorcontrib>Tavares-Murta, Beatriz</creatorcontrib><creatorcontrib>Murta, Eddie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nomelini, Rosekeila</au><au>Carrijo Chiovato, Ana</au><au>Abdulmassih, Fernanda</au><au>da Silva, Rafael de</au><au>Tavares-Murta, Beatriz</au><au>Murta, Eddie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>15</volume><issue>6</issue><spage>1226</spage><epage>1230</epage><pages>1226-1230</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Objective: The objectives of the present study were to demonstrate the influence of neutrophils, platelets, and neutrophil-lymphocyte ratio (NLR) in the ovarian cancer prognosis and to compare these parameters with benign ovarian neoplasms.
Materials and Methods: Records of patients underwent surgery for ovarian cysts were evaluated. There were 72 malignant neoplasms and 213 benign neoplasms. Age, parity, histologic type, tumor stage, type of surgery performed, chemotherapy, disease-free survival, serum levels of tumor markers, neutrophils, lymphocytes, platelets, and NRL were recorded. The Mann-Whitney, the Chi-square test and multiple linear regression were used. A P-value < 0.05 was established as the significance level.
Results: Higher values of platelets, neutrophils, and NLR were found in malignant tumors (P = 0.0132, P = 0.0208, and P < 0.0001, respectively), while lymphocytes values were higher in benign group (P < 0.0001). Preoperative platelet count 300,000/mm3 was related to less aggressive histological types (P = 0.0148). NLR <3 was related to the initial stages (P = 0.0053), and patients with disease-free survival >24 months had most often neutropenia during chemotherapy (P = 0.0482). After multivariate analysis, platelets, NLR, and serum levels of CA15.3 were considered independent variables related to tumor staging (P = 0.028, P = 0.028, and P = 0.035, respectively).
Conclusion: NLR and serum levels of platelets may represent potential prognostic factors in ovarian cancer, and they may also serve as therapeutic targets in the future treatment strategies.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>31898652</pmid><doi>10.4103/jcrt.JCRT_304_17</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2019-10, Vol.15 (6), p.1226-1230 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2333600739 |
| source | MEDLINE; Medknow Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Biomarkers Blood platelets Blood tests Cancer therapies Chemotherapy Clinical Decision-Making Cysts Disease Disease Management Female Humans Leukocyte Count Lymphocyte Count Lymphocytes Medical prognosis Metastasis Neoplasm Grading Neoplasm Staging Neutropenia Neutrophils Ovarian cancer Ovarian Neoplasms - blood Ovarian Neoplasms - diagnosis Ovarian Neoplasms - mortality Ovarian Neoplasms - therapy Patients Platelet Count Prognosis Regression analysis Software Surgery Tumors |
| title | Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A36%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil-to-lymphocyte%20ratio%20and%20platelet%20count%20as%20prognostic%20factors%20in%20ovarian%20malignancies&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Nomelini,%20Rosekeila&rft.date=2019-10-01&rft.volume=15&rft.issue=6&rft.spage=1226&rft.epage=1230&rft.pages=1226-1230&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.JCRT_304_17&rft_dat=%3Cproquest_cross%3E2333600739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2330748762&rft_id=info:pmid/31898652&rfr_iscdi=true |